Literature DB >> 26559576

Targeting Stem Cells in Chronic Myeloid Leukemia with a PPAR-γ Agonist.

Josephine M Egan.   

Abstract

Combining a tyrosine kinase inhibitor (imatinib) and a thiazolidinedione (pioglitazone) is proposed for the treatment of chronic myeloid leukemia.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26559576     DOI： 10.1056/NEJMcibr1511276

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


  5 in total

Review 1.  PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis.

Authors:  Veronica Vella; Maria Luisa Nicolosi; Stefania Giuliano; Maria Bellomo; Antonino Belfiore; Roberta Malaguarnera
Journal:  Front Endocrinol (Lausanne)       Date:  2017-02-22       Impact factor: 5.555

Review 2.  Peroxisome Proliferator-Activated Receptor γ and PGC-1α in Cancer: Dual Actions as Tumor Promoter and Suppressor.

Authors:  Seong-Hoon Yun; Sang-Heum Han; Joo-In Park
Journal:  PPAR Res       Date:  2018-01-21       Impact factor: 4.964

Review 3.  Nuclear Receptors as Potential Therapeutic Targets for Myeloid Leukemia.

Authors:  Pan Pan; Xiao Chen
Journal:  Cells       Date:  2020-08-19       Impact factor: 6.600

4.  Synthesis and Characterization of Telmisartan-Derived Cell Death Modulators to Circumvent Imatinib Resistance in Chronic Myeloid Leukemia.

Authors:  Anna M Schoepf; Stefan Salcher; Verena Hohn; Florina Veider; Petra Obexer; Ronald Gust
Journal:  ChemMedChem       Date:  2020-05-06       Impact factor: 3.466

Review 5.  Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis.

Authors:  Peng Zeng; Alvin Schmaier
Journal:  Int J Mol Sci       Date:  2020-09-08       Impact factor: 6.208
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.